Sanofi's Tolebrutinib Receives Complete Response Letter From FDA
I'm PortAI, I can summarize articles.
Sanofi SA :PROVIDES UPDATE ON TOLEBRUTINIB REGULATORY SUBMISSION IN NON-RELAPSING SECONDARY PROGRESSIVE MULTIPLE SCLEROSISUS FOOD AND DRUG ADMINISTRATION (FDA) HAS ISSUED A COMPLETE RESPONSE LETTER (CRL) FOR NEW DRUG APPLICATION OF TOLEBRUTINIB
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments